Navigation Links
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Date:6/16/2008

>SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the potential safety, efficacy, duration of response and commercial potential of voreloxin (formerly SNS-595); planned additional clinical testing and development efforts for voreloxin; the timing of enrollment in the ongoing clinical trials of voreloxin; and the timing of announcements of results of ongoing clinical trials of voreloxin. Words such as "promising," "encouraging," "hope," "appears," "demonstrate," "indicates," "supports," and "look forward" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis' development activities for voreloxin, including enrollment and reporting of results, could be halted significantly or delayed for various reasons; the risk that Sunesis' clinical trials for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval; the risk that preliminary data and trends including data regarding duration of response, may not be predictive of future data or results; the risk that Sunesis' preclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies; risks related to the conduct of Sunesis' clinical trials and manufacturing; and risks related to Sunesis' need for additional funding. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Annual Report on Form 10-K for the year ended December 31, 2007, Sunesis' Quarterly Report on Form 10-Q fo
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
4. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
5. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
9. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
10. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... MEADOWS, N.Y. , Dec. 15, 2014 ... the SPL (Structured Product Labeling) markup language standard, content ... the understanding and skills to work with the standard. ... a series of three webinars on the benefits and ... three one-hour webinars will be facilitated by Howard ...
(Date:12/14/2014)...  ChartSpan, a consumer platform for patients managing healthcare ... medical app in the United States ... ChartSpan is an iPhone and iPad app ... send electronic healthcare records. The product was built by ... waiting for the healthcare system to deliver on the ...
(Date:12/13/2014)... Dec 12, 2014 Mindray Medical International Limited ... manufacturer and marketer of medical devices worldwide, today announced ... shareholders held in Hong Kong ... Mindray shareholders voted to re-elect incumbent directors Li Xiting ... Mindray,s shareholders did not re-elect Peter Wan ...
Breaking Medicine Technology:Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 2Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 3ChartSpan Becomes The Most Downloaded Medical App in America 2ChartSpan Becomes The Most Downloaded Medical App in America 3Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2
... International Holdings , Inc. (NYSE Amex: BONE ... graft material and antimicrobial coatings for medical applications, has ... national investor relations firm, to develop and implement a ... strengthen its relationships with the investment community. ...
... 1, 2012   IntraOp Medical Corporation   (OTC: IOPD) ... dismissed the patent nullification case that IntraOp Medical had ... for a mobile IOERT linear accelerator with "straight through" ... slight clarification. IntraOp Medical,s European Patent ...
Cached Medicine Technology:Bacterin Retains Hayden IR to Develop Strategic Investor Relations Program 2Bacterin Retains Hayden IR to Develop Strategic Investor Relations Program 3Bacterin Retains Hayden IR to Develop Strategic Investor Relations Program 4IntraOp Medical wins Patent Defense Suit Protecting Their Intellectual Property 2IntraOp Medical wins Patent Defense Suit Protecting Their Intellectual Property 3
(Date:12/15/2014)... researchers have just published an important new report on ... mesothelioma. Surviving Mesothelioma has just posted an article on ... read it now. , Doctors at Harvard, MIT, ... Langone Medical Center performed complete genetic analyses on 22 ... to pinpoint the genes that are most likely to ...
(Date:12/15/2014)... Street Dental Team ( http://www.MainStreetDentalTeam.com ), Unionville’s first full-time ... providing evidence on the impact of 100% pure fruit ... enough evidence already exists showing a negative link between ... the onset of tooth decay. One question that has ... fruit juice, meaning it is completely natural with no ...
(Date:12/15/2014)... 2014 SIMpalm, a leading mobile ... for iPhone for its client, which allows users to ... company, specialized in finding the right wine. At ... uses combined sensory, chemistry and wine information. All this ... “wine fingerprint.” Those wines that are close counterparts to ...
(Date:12/15/2014)... 2014 Health Dialog, a leading ... that it has received Patient Oriented Accreditation from ... its Disease Management (DM) Programs for asthma, congestive ... heart disease and diabetes. This marks the 12th ... Dialog’s Disease Management (DM) Programs, reaffirming Health Dialog’s ...
(Date:12/15/2014)... (HealthDay News) -- Expert pilots process visual information more ... make better decisions during landings, a new study shows. ... for pilots to master, and 36 percent of all ... during final approach and landing. Researchers monitored the ... experienced pilots while they were at the controls of ...
Breaking Medicine News(10 mins):Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Study Shows Why Expert Pilots Are Experts 2
... ... and provides healthy lifestyle message. , ... (Vocus) April 1, 2010 -- AthletiCo Physical Therapy and Occupational Therapy has signed a ... the 7th Inning Stretch Fan Cam for the 2010 through 2012 Major League Baseball (MLB) ...
... they know how cytomegalovirus continues to re-infect people , THURSDAY, ... how a virus known as cytomegalovirus (CMV), which infects up ... re-infects people again and again even though their immune systems ... always make people ill, but certain people, such as newborns ...
... with hepatitis C are fine for patients with the ... News) -- Every year, hundreds of kidneys are thrown ... but they could help many hepatitis C-infected patients waiting ... fact, since 1995, more than 3,500 kidneys infected with ...
... a cell wall and fuse with it could offer researchers ... of individual cells. Everything from signals generated as cells ... to medication could be monitored for up to a week, ... are so destructive they usually only allow a few hours ...
... of cancer cells to resist treatment with either targeted ... result from a transient state of reversible drug "tolerance." ... journal Cell and is receiving early online ... Center report finding small populations of drug-tolerant cells from ...
... Dr. Daniel D. Von Hoff, Physician-in-Chief for the Translational ... the American Society of Clinical Oncology (ASCO) for his cancer ... 2010 David A. Karnofsky Memorial Award and Lecture at ASCO,s ... Chicago. ASCO will present the award to Dr. Von ...
Cached Medicine News:Health News:AthletiCo Physical and Occupational Therapy and Chicago White Sox Partner for 7th Inning Stretch Fan Cam 2Health News:AthletiCo Physical and Occupational Therapy and Chicago White Sox Partner for 7th Inning Stretch Fan Cam 3Health News:Demystifying a Common, Persistent Virus 2Health News:Hundreds of Donor Kidneys Tossed Away Each Year 2Health News:Hundreds of Donor Kidneys Tossed Away Each Year 3Health News:Nanoscale 'stealth' probe slides into cell walls seamlessly, say Stanford engineers 2Health News:Nanoscale 'stealth' probe slides into cell walls seamlessly, say Stanford engineers 3Health News:Treatment resistance in some cancer cells may be reversible 2Health News:TGen Physician-In-Chief Dr. Daniel D. Von Hoff wins ASCO award 2
Rheumatoid factor calibrator (Latex enhancedimmunoturbidimetric)...
Fructosamine Calibrator...
CRP high sensitivity calibrator series...
CRP Calibrator...
Medicine Products: